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ABSTRACT  
Based on WHO statistics, counterfeit medicines represent 10% of the global 
drug trade. According to Directive 2011/62/EU as regards the prevention of 
falsified medicines from entering into the legal supply chain, a unique 
identification should be put on each box of drugs to be able to track and trace 
them. The objective of this study is to develop a technology to mark an 
individual traceability code directly on the surface of the tablet. By using this 
technique, anyone with a camera-enabled phone and a suitable application 
installed should be able to authenticate these drugs. By marking the medicine’s 
surface, patients could be protected from fake drugs. 
The aim of the present work was to study how different types of lasers affect 
the film coating of the tablet during the laser marking intervention. 
To sum up, the present findings may contribute to efficient and reliable laser 
marking solutions in the unique identification procedure. Based on our 
measurement results, it can be stated that the excimer UV laser is clearly the 
most suitable marking instrument for anti-counterfeiting coding on solid coated 
tablet form as this caused the least amount of chemical degradation of the 
polymer film. 
 
 
 
 
 
 
 
 
 
 
 
Keywords: falsified medicines, identification, anti-counterfeiting, laser marking, 
unique laser coding, safety 
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1. Introduction 
In the interest of avoiding misunderstanding, it is important to remark that the 
expression counterfeit medicine used in this article comprises the WHO’s 
definitions for substandard (authorized medical products that fail to meet 
either their quality standards or specifications, or both), unregistered (that 
have not undergone approval by the National or Regional Regulatory Authority 
for the market in which they are distributed), and falsified (that deliberately 
misrepresent their identity, composition or source) medical products (WHO, 
2018). 
Counterfeit drugs pose a great threat for health and they cause serious social 
and economic damage. Based on WHO statistics, it is estimated that 1 in 10 
medical products is substandard or falsified in low- and middle-income 
countries where health systems are weak or non-existent (WHO, 2018). The 
most frequently falsified medicines in wealthy countries were lifestyle 
medicines, such as hormones, steroids and antihistamines. In developing 
countries, they included medicines used to treat life-threatening conditions 
such as malaria, tuberculosis and HIV / AIDS (European Medicines Agency, 
2018). 
It is  threatening that medicines purchased over the Internet from sites that 
conceal their actual physical address are counterfeit in over 50% of cases 
(UNICRI, 2012; WHO IMPACT, 2006). 
A culture of self-diagnosis and self-prescribing has led to the emergence of 
thousands of unregulated websites providing unsupervised access to 
substandard and falsified medical products. Unregulated websites, social media 
platforms, and smartphone applications can also be direct conduits of 
counterfeit medical products (WHO, 2018). Patients across the world put their 
health, even life, at risk by unknowingly consuming fake drugs or genuine drugs 
that have been badly stored or that have expired (Interpol, 2013). 
Responsible governments prohibit falsified medicines under national law but 
remain vulnerable to organized criminals doing business in countries where 
laws or enforcement are lax—30% of countries have little or no medicine 
regulation according to WHO (Attaran et al., 2012). 
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Globally, there are around 30,000-35,000 online pharmacies. 96% of these 
operate illegally. They do not comply with regulatory and safety requirements 
and they may sell prescription drugs without a valid prescription. On average, 
20 online pharmacy websites are created each day (CSIP, 2016). 
Falsified medicines in the legal supply chain are less prevalent in the EU, but 
this trend seems to be on the rise. 2 cases reported in 2012 vs. 12 in 2013 and 
15 in 2014 (European Commission Staff Working Document, 2015). For 
example, in 2014 falsified vials of the cancer treatment Herceptin 
(trastuzumab) were stolen in Italy, manipulated and later reintroduced illegally 
into the legal supply chain in some countries (European Medicines Agency, 
2014; Sukkar, 2014). 
A European Union Intellectual Property Office (EUIPO) report shows that fake 
medicines cost the EU pharmaceutical sector EUR 10.2 billion (4.4% of sales) 
each year. This is a direct estimate of sales lost by legitimate manufacturers 
and wholesalers of medicines in the EU due to counterfeiting. Moreover, 
37,700 jobs and EUR 1.7 billion of government revenue are lost annually 
(household income taxes, social security contributions and corporate income 
taxes ) (Wajsman et al., 2016). 
The links between drug counterfeiting and other forms of crime are proven 
both by the methods used and the nature of the products that are regularly 
seized. Counterfeiting is a world-wide problem. Traffickers have a single 
motivation: extreme profitability. In the study report written by Eric Przyswa he 
has given an example: according to the International Federation of 
Pharmaceutical Manufacturers and Associations (IFPMA), for $1,000 invested, 
the trafficking of counterfeit currency or of heroin would bring a return of 
$20,000, of counterfeit cigarettes $43,000, and in the case of counterfeit drugs, 
the return would be between $200,000 and $450,000. Counterfeit drugs would 
therefore be 10 to 25 times more profitable than the trafficking of narcotics. 
The major distribution vehicle is the Internet, which is decentralized and 
anonymous. The malleability and permanent interconnection of networks seem 
to offer genuine opportunities for illicit trafficking. (A Royal Pharmaceutical 
Society Publication, 2014; IRACM, 2013; Przyswa, 2013). 
According to Directive 2011/62/EU as regards the prevention of falsified 
medicines from entering into the legal supply chain, a unique identification 
should be put on each box of drugs (The European Parlament and the Council 
of the European Union, 2011). The new Delegated Regulation 161/2016/EU 
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shall enter into force from 9 February 2019, which, besides serialization 
requirements, demands additional anti-tampering devices for drug packaging. 
In Europe pharmaceutical manufacturers who distribute their products must, in 
the future, assign prescription medications with a serial code as a unique 
identification feature, save this serial number and transfer it to a Europe-wide 
database under the tightest security requirements. The security code specified 
by the EU is a 2D data matrix code that ensures traceability along the entire 
supply chain (European Comission, 2016). 
Our team would like to extend this process by working on the development of a 
technology to mark an individual traceability code directly on the surface of the 
tablet. Anyone with a camera-enabled phone and a suitable application 
installed on it should be able to authenticate these drugs. Also, as in certain 
Member States the persons authorized or entitled to supply medicinal products 
to the public are allowed to open a pack of a medicinal product in order to 
supply part of that pack to the public, it is necessary to verify those drugs in 
question, too (A Royal Pharmaceutical Society Publication, 2017; European 
Comission, 2016). We plan that our development with on-product marking 
would help to verify each pill even in the absence of original packaging. 
The ideal mark for medical applications is indelible, easy to read, difficult to 
copy or alter, contains unique serialization information, and does not change 
product functionality in any way (Heller, 2015). 
Film coating is used in the pharmaceutical industry for solid dosage form 
because of visual attractiveness, trade marking issues, identifying, taste 
masking, improved product stability, shelf life increase or controlled release of 
the active pharmaceutical ingredient (API) (Koller et al., 2011; Korasa et al., 
2016; Markl et al., 2014). Besides the above, colored coatings can also help to 
prevent counterfeiting. Since most of the tablets are round and white and, 
consequently, easier to fake, a unique and distinctive shape and color can 
improve identification and make counterfeiting more difficult (Pérez-Ibarbia et 
al., 2016).  
Coloring and special shape are not enough to distinguish each tablet from one 
another. Further marking is necessary, especially for unique identification. 
From among many different options, printing is one of the most attractive 
methods for marking as the capital equipment cost is relatively low. However, 
the printing process necessitates contact between the substrate and some 
form of ink carrier, toner reservoir, or stamp, so it could be a source of 
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contamination. High printing speed is required for some of the fastest 
production lines and that can result in a loss of image quality and the risk of 
unreadable codes (Davison, 2011). Furthermore, the ink formulation has to be 
designed with respect to its viscosity and surface tension to guarantee 
continuous printing and high reproducibility of the forming droplets (Genina et 
al., 2012). In addition, chemical markers or colorants that are used on the 
surface of the dosage form must be materials that are tested and accepted as 
safe by the pharmaceutical authorities (Davison, 2011).  
One of the other ways of marking could be done with infrared (IR) laser. It 
produces a surface mark through intense localized heating and it could cause 
damage in heat-sensitive materials (Gaebler, 2017). 
 
Ultraviolet (UV) lasers overcome the drawbacks of the above-mentioned ink 
printing and IR laser printing technologies. UV laser marking is a non-contact 
method that avoids the problems of contamination and eliminates the cost of 
consumables. It undergoes a cold photochemical, rather than photothermal 
interaction. Since this is a cold process, there is essentially no Heat Affected 
Zone (HAZ) or changes to the surrounding material. Finally, since UV light can 
be more tightly focused than IR, UV lasers support complex, high-resolution 
marks such as 2D barcodes. 
In the past UV lasers were rarely utilized because of their cost. However, over 
the past decade, companies reduced UV laser price by a factor of nearly five 
over this period (Heller, 2015). 
The final aim of the present work is to develop a technology to mark an 
individual traceability code directly on the tablet. The plan is to make 2 layers 
of coatings on the surface. The first one is the functional one, and the other on 
the top of it would be applied because of the marking. The colors of the 2 
coatings should contrast each other. By ablating the upper coating, we should 
be able to read the 2D data matrix code that will be formed of those two 
layers. The basic experiment for this article started with only one layer. We 
examined how the coated film behaves when it is treated with 3 different types 
of laser to be able to select the right instrument for further research. With 
excimer UV laser we made a square shape ablation for a start, which we plan to 
replace in the future with 2D code forming mask. With semiconductor laser we 
were able to mark a 2D barcode on the surface of the tablet. Unfortunately, the 
pulsed Nd:YAG laser damaged the coating film.  By analytical quality tests, we 
were planning to select the right instrument for unique drug marking. 
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This investigation suggests the use of excimer UV laser for marking the tablet 
surface because this treatment minimizes the chemical degradation of the 
coating film during the process. 
2. Materials and methods 
2.1. Materials 
2.1.1. Tablet core and coating materials 
Tablet samples for laser marking preformulation were original tablets from the 
legal supply chain: Sinecod (GSK), Telfast (Sanofi), Klacid (Abbott), furthermore 
Eudraguard® control and HPMC coated placebo tablets. 
In the further research round placebo tablets were used, with no break line 
(diameter: 7mm, crown height: 4mm). Aqueous-based enteric coating solution 
was prepared. It consisted of 52% w/w dry substance of a neutral copolymer 
based on ethyl acrylate and methyl methacrylate with a ratio of 2:1 
(Eudraguard® control dispersion 30% w/w (Evonik Nutrition & Care GmbH)), 
16% w/w talc, 28 % w/w alginic acid sodium salt, 4 % w/w glycerol, and distilled 
water. Coatings were colored with 1% w/w patent blau 85 (blue), 3% w/w 
Gelborange (orange), 1.5% w/w Azorubin (cherry) or 1.5% w/w Iron Oxide Red 
(red). 
2.2. Methods 
2.2.1. Tablet coating procedure 
The spray coating process was performed using a 4M8 Pancoat (Pro-C-epT, 
Zelzate, Belgium) perforated coating pan on a batch of 500g tablet. The process 
was divided into three stages. The coating parameters are shown in Table 1. 
For the application of the atomized spray coating solution, 0.8 mm spray nozzle 
was used for 140 minutes, with an atomizing air pressure of 1.5 bars and an air 
flow rate of 0.50 m3/min. The drying and cooling processes together lasted for 
30 minutes. 
The final coating thickness was determined by Zeiss Stereomicroscope. 
Measurements were performed at a magnification of 500. After calibration, we 
examined 4-4 half-cut tablets (differently colored), each at 10 places. Coating 
thickness averages measured on different tablets are: yellow: 60.79±9.11 µm, 
blue: 59.31±11.82 µm, cherry: 49.19±10.18 µm and red: 88.02±18.98 µm. 
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2.2.2. Irradiation of tablets using 3 types of laser 
The coated tablets were irradiated with a pulsed Lambda Physik EMG 201 type 
ArF excimer laser (wavelength: 193 nm, energy: 3±0.2mJ, fluence: 444 mJ/cm2, 
FWHM: 20 ns, spot size: 375 µm), CW (continuous wave) semiconductor laser 
(wavelength: 405 nm, spot size: 73 µm, power: 1000 mW, irradiation time: 15-
20 ms) and pulsed Nd:YAG laser (wavelength: 1064, power: 1-2.6 W, frequency: 
1 kHz).  
2.2.3. Surface profilometer 
Profilometry measurements were performed on a Veeco, Dektak 8 Advanced 
Development Profiler®.  The tips employed had a radius of curvature ~2.5 µm, 
and the force applied to the surface during scanning was ~30 µN.  The 
horizontal resolution was 0.1-0.13µm.  The vertical resolution was 40 Å. 
Data has been evaluated by Dektak software (Microsoft ® Windows XP ®: 
interactive data acquisition) and Vision ® 32 software (data processing, 2-D and 
3-D image analysis) (Veeco Instruments Inc., New York, USA) 
2.2.4. Scanning electron microscope (SEM) 
The morphology of the ablated film was observed by using a scanning electron 
microscope (SEM, Hitachi Tokyo, Japan S4700). The tablets were stuck to a 
double-sided carbon adhesive tape and a conductive golden layer was 
deployed with the use a sputter apparatus (Polaron Ltd., UK). The 
measurements were performed at a magnification of 100–2000, applying 10.0 
kV of electron energy and 1.3–13 MPa of air pressure. 
2.2.5. Raman spectra 
In our method, the effect of laser light was analyzed by Raman surface 
mapping. To investigate the components, Raman spectra were acquired with a 
Thermo Fisher DXR Dispersive Raman (Thermo Fisher Sco. Inc., Waltham, MA, 
USA) equipped with a CCD camera and a diode laser operating at a wavelength 
of 780 nm. Raman measurements were carried out with a laser power of 6 and 
24 mW at 25 µm slit aperture size on a 2 µm spot size. The spectra of the 
individual substances were collected using an exposure time of 6 sec, a total of 
48 scans in the spectral range of 1700-200 cm-1 with cosmic ray and 
fluorescence corrections. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
9 
 
2.2.6. Thermal gravimetric analysis (TGA) 
The thermal gravimetric analysis of the samples was carried out with a Mettler-
Toledo TGA/DSC1 instrument (Mettler-Toledo GmbH, Switzerland). The start 
temperature was 25°C, the end temperature was 500°C, the applied heating 
rate was 10°C / minute. Nitrogen atmosphere was used (Cell gas: 50 ml/ min, 
method gas: 70 ml/ min). 5±1 mg samples were measured into aluminum pans 
(40 μl). The TG curves were evaluated with Mettler-Toledo STARe Software.  
2.2.7. Mass spectrometry (MS) 
The gas analysis of the tablet coating material was carried out with the Thermo 
Star (Pfeiffer Vacuum, model ThermostarTM GSD 320, Germany) quadruple 
mass spectrometer (maximum 300 amu) for gas analysis that was coupled to 
the TG instrument. The measurements were carried out in a flow of nitrogen 
atmosphere. The connection between the TG and the mass spectrometer was 
made by means of a silica capillary, which was maintained at 120°C. Ions with 
various mass numbers were determined with the SEM MID measurement 
module of the Quadera software. Continuous recordings of sample 
temperature and sample mass were performed. The obtained results were 
exported and then plotted in one coordinate system with the TG curves using 
the Mettler-Toledo STARe software. 
3. Results and discussion 
Coated tablets were marked with 3 different types of lasers. After marking 
polymer films, we made an analytical quality control of them to check if there 
occurred any change during the laser intervention.  
Since the Nd: YAG laser treatment burned the tablet’s coating during the 
preformulation study, that tool was not a part of our further research. The 
treatment result is presented in Figure 1. 
3.1. Examination of tablet surface 
Firstly, film coted tablets were treated by excimer laser with 10, 20, 30, 40, 50, 
60, 70 and 80 pulses, which is seen in Figure 2, Part A. The holes have a shape 
of a regular square, sharply separated from the environment, returning the 
shape of the mask used. Secondly, coated tablets were treated by 
semiconductor laser. With this instrument we were able to mark a two-
dimensional QR code on tablets. The photograph of it can be seen in Figure 2, 
part B. It shows that the laser beam blackened the coating. Factors changing 
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the color of the coating by the semiconductor laser irradiation were not 
cleared. 
The ablated holes of the excimer laser were examined by a surface 
profilometer and their extent was measured. Also, the influence of the 
differently colored coatings on the ablative depth was examined.  
The results of profilometer were evaluated as follows: the raw data were 
detrended by fitting the second order polynomial to the region not affected by 
laser treatment (Figure 3). This correction was applied to the data in order to 
eliminate the tablet curvature effect. The obtained data was used to calculate 
the ablation depth by fitting a line to the points in the ablation hole. The 
distance of the line segment’s center point from zero level was assumed as the 
average ablation depth (Figure 3). 
The results of the ablations on the blue colored tablet are shown in Figure 4. 
The curves in the left figure show the deepness of the holes made by different 
numbers of laser pulses. The measurements and the fitted line in the right 
figure show near lineal relation between the applied number of impulses and 
ablation depth up to 100 impulses. 
The series of the ablated holes were examined with a full profilometer scan on 
the red tablet surface (Figure 5). The tablet coating was treated by excimer 
laser using 10, 20, 30, 40, 50, 60, 70, 80, 90 impulses. The ablation depths were 
also calculated by extracting the affected regions from the dataset. The 
aggregated data show a similar linear relation between the applied number of 
impulses and ablation depth as was determined in the case of other colors. 
We found some influence of the different colors on the ablation depth (Figure 
6). The quantitative analysis of this effect needs more profilometer and optical 
property measurements. The weighted average of the ablation performance is 
0.411 ± 0.025 µm / impulse using 2.8-3.2 mJ impulses in Eudraguard® control 
film. 
3.2. Scanning electron microscope  
The pre- and post-laser structure was examined by SEM as well. In Figure 7, 
Parts A, B the micrographs of the film treated with excimer laser can be seen. 
They show the same ablation square at different magnifications. It is seen that 
the ablated surface of the sample exhibits no large destructions, the structure 
of the film is relatively intact. The shape of the hole is a well distinguished 
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regular square, returning the shape of the mask used. It is clearly visible at the 
edge of the ablative pit that the film has a layered texture due to the drying of 
droplets during the coating procedure. It looks as if these layers came off one 
after another in accordance with the number of laser impulses used. Despite 
the lack of bigger destructions, there are some cracks in the affected area, 
which may be the result of loss of water caused by the local temperature 
elevation or by a photocatalytic reaction. 
Part C of Figure 7 shows that, in contrast with the excimer laser, the 
semiconductor laser induced considerable damage in the coating structure 
during the treatment. Holes are seen in every 200µm on the film, surrounded 
by a wide range of burn traces. There are blistering, snow-flake like crystals 
around the holes, melting, and recrystallization. It is unclear whether these are 
the results of a consequential loss of water or the melting of the coating 
material. 
The changes described above were observed macroscopically. In the following, 
the chemical structure degradation was analyzed by Raman and TG-MS 
analytical tests. 
3.3. Raman investigations 
Raman spectroscopy is a promising analytical method to monitor the 
preparation process and to implement the PAT requirements. In this article, a 
Dispersive Raman spectrometer was used to detect the effect of different laser 
sources on the surface of coated tablets. Raman Spectroscopy is used for the 
non-invasive and fast, qualitative investigation of pharmaceutical dosage 
forms. 
To investigate the effect of different laser sources on film coating, we used 
Raman spectroscopy. The finger print region of Eudraguard® control is 1800 
cm-1 – 500 cm-1. In Figure 8 we summarized the spectra of raw film dispersion, 
raw free film and films treated by different laser sources. The spectra of the 
film treated by semiconductor laser changed completely, the fingerprint region 
of Eudraguard® control smoothed. The result of this laser treatment, black 
burst signal, is seen in the microscopic picture (Figure 9, Part B). The square 
shaped ‘print’ on the surface of the film returned the shape of the mask used 
after the excimer laser ablation (Figure 9, Part A). 
To confirm the chemical degradation of the film polymer, Raman chemical 
mapping was chosen. We selected an area treated by semiconductor laser 
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which contained burst and intact film, too. The microscopic mosaic photo is 
presented in Part A of Figure 10. The area framed with blue lines is the 
chemically mapped part. The spectra were determined in the blue points. Then 
this chemical map was profiled to the special changed area of the spectra 
which was treated by semiconductor laser (1800 cm-1 – 500 cm-1). The warm 
colors show the area which contains these spectra (Part B of Figure 10). Then 
the chemical map was profiled to the untreated Raman spectra of the film 
coating (Part C of Figure 10). In this picture the warm colors show the original 
(raw) intact film. This picture is the inverse of Part B of Figure 10. So, we have 
concluded that chemical changes were caused by the semiconductor laser 
source. 
3.4. Thermal gravimetric analysis (TGA) 
TGA is a method of thermal analysis which provides curves corresponding to 
mass loss characteristics. As the measured substance degrades, basic 
information is given about their behavior during temperature rise. Data from 
mass reduction through this system alone does not allow classification of the 
molecules. 
The burning characteristics of samples obtained from thermogravimetric 
analysis may be used to effectively compare the decomposition characteristics 
of the raw polymer film and films treated by different laser beams. 
Table 2 shows TG temperature ranges, mass loss, DTG normalized integral of 
examined materials and peak temperatures. The main characteristics of the 
samples derived from TG curves as corresponding mass loss values were used 
to define the thermal behavior and combustion characteristics of films.  
It is seen that mass loss in coating films comes in three stages. The first mass 
loss occurred between 30 and 120°C, the second stage between 120-290°C, 
and the third between 290–500°C. Thermogravimetry showed that the 
decomposition of the material occurred sooner in films marked by 
semiconductor laser, in higher temperature ranges, which is probably due to 
the decomposition process that had already started during the laser marking 
process. We did not experience anything like this in the case of using excimer 
laser. 
3.5. Evolved gas analysis with mass spectrometry 
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To clarify the decomposition mechanism of the films, the mass loss should be 
characterized during each decomposition process by the identified evolution of 
gas components. The mass spectra were interpreted on the basis of degassing 
profiles of the molecule ions and ion fragments of various gases. 
The evolution of released gas species was followed in situ by the coupled 
system of TG-MS instruments. The evolution curves are shown as current ion 
versus time curves. The characterization of water release by means of MS is 
possible with the molecule H2O, m/z=18, (peak at 50°C). It can be safely 
concluded from Figure 11 that water is given out at about 50°C from the 
samples, which is consistent with the mass loss observed from the TG curves. 
The dehydration of the film takes place at around this temperature. 
An important increase in the concentration of methyl methacrylate is recorded 
for m/z=41 and for m/z=69 due to the decomposition of the polymer at 
temperatures at around 360 °C. The abundance of the m/z=41 and m/z=69 
signals vs. temperature can be seen in Figure 11. The m/z=69 signal 
corresponds to the monomer after the loss of –OCH3 from the side chain, and 
the m/z=41 signal corresponds to the monomer after the loss of the entire side 
chain (–COOCH3). 
The evolution of gas of CO2, m/z=44 signal was detected in two steps at slightly 
higher temperatures around 240°C and 365-370°C, as it is seen on the MS 
curves in Figure 11. 
The release of ethanol, m/z=31 by means of MS curves seen in Figure 11, 
happens at a temperature around 355°C. 
The results of mass spectroscopy are consistent with the mass loss observed 
from the TG curves, as the decomposition of the material occurred slightly 
sooner in the film treated with semiconductor laser in the case of m/z=44 and  
m/z=69, where the decomposition started sooner as the deacylation had taken 
place earlier during the laser treatment. 
Also, there were other gases evolved from the treated material, which are 
under examination for the interpretation of further mass loss difference seen in 
the TG curves of the original film compared to the films treated by lasers. 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
14 
 
4. Conclusions 
Anti-counterfeiting unique laser marking of the tablet surface operation was 
investigated in this article. 
It was found that from among the three types of coding instruments examined, 
excimer laser ablation did not cause a qualitative change in the material during 
laser marking. 
In this study we examined how the depth of ablation can be controlled by 
changing only the number of impulses delivered by excimer laser. We found 
that the correlation is completely linear. We were able to ablate even 100 µm 
deep in the coating, so it is possible to trim the outer layer even if it is that 
thick.  
Raman spectroscopy is becoming one of the most widely used and applicative 
approaches for analyzing pharmaceutical materials. It was shown that Raman 
was capable of distinguishing films treated by different laser sources. We have 
concluded that chemical changes were caused by semiconductor laser source 
compared to the original film, and the film treated by excimer laser. 
The main finding of the TG measurement showed that the decomposition of 
the material occurred sooner in films marked by semiconductor laser, in higher 
temperature ranges, which is probably due to the decomposition process that 
had already started during the laser marking intervention. We did not 
experience anything like this in the case of using excimer laser. 
Based on our measurement results, it can be stated that the excimer UV laser is 
clearly the most suitable marking instrument for anti-counterfeiting coding on 
solid coated tablet form. 
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Figure 3. The ablation depth calculation process 
Figure 4. The profilometer analysis of the ablated holes 
Figure 5. The profilometer analysis of the red tablet surface 
Figure 6. Comparison of the measurements of the ablated hole depth of 
tablets with different colors 
Figure 7. The SEM micrograph of excimer laser treated film (magnification of 
100x:A, magnification of 500x:B) and semiconductor laser treated 
film (magnification of 200x:C) 
Figure 8. Raman spectra of film coatings (A: Eudraguard® control dispersion, 
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Table 1. Coating parameters of placebo tablets 
Step inlet-air 
temperature 
(°C) 
exhaust-air 
temperature 
(°C) 
tablet bed 
temperature 
(°C) 
drum 
speed 
(rpm) 
air flow 
rate 
(m3/min) 
warm up 50  until 30 5 0.50 
coating 49±2 32 30±2 18 0.50 
drying & 
cooling 
40 27 25 5 0.50 
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Table 2. Decomposition behavior of the raw polymer film and the film treated 
by laser 
TG-DTG data Eudraguard® 
control film 
Eudraguard® 
control film 
treated with 
excimer laser 
Eudraguard® 
control film 
treated with 
semiconductor 
laser 
    
First step    
Thermal range (°C) 30-120 30-120 30-120 
Mass loss (%) 4.31 3.90 4.12 
Normalized integral (s/°C) -0.11 -90.41e-03 -0.13 
Peak (°C) 72.83 57.03 64.65 
    
Second step    
Thermal range (°C) 120-290 120-290 120-290 
Mass loss (%) 15.03 14.28 18.75 
Normalized integral (s/°C) -0.57 -0.59 -0.60 
Peak (°C) 232.99 233.74 230.66 
    
Third step    
Thermal range (°C) 290-500 290-500 290-500 
Mass loss (%) 50.59 51.88 69.96 
Normalized integral (s/°C) -2.12 -2.12 -2.79 
Peak (°C) 362.78 360.07 358.40 
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